ClinicalTrials.gg
CompletedNCT01385657Updated Feb 26, 2020

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

A Phase 1 interventional study of Placebo and Dupilumab in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-26.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
37th of 50
37 · median 75
Started
2011
the only one that year
Phase 1
4 of 50
none open now
Registered
1st of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 37th largest by enrollment, is the only one that started in 2011, is one of 4 in phase 1, and was the 1st registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 years or older;
  2. Chronic AD diagnosed by the Eichenfield revised criteria of Hannifin and Rajka that had been present for at least 3 years before the screening visit;
  3. Eczema Area and Severity Index (EASI) score ≥ 12 at the screening and baseline visits;
  4. Investigator's Global Assessment (IGA) score ≥ 3 at the screening and baseline visits;
  5. ≥ 10% body surface area (BSA) of AD involvement at the screening and baseline visits;
  6. History of inadequate response to a stable (≥ 1 month) regimen of topical or calcineurin inhibitors as treatment for AD within 3 months before the screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Positive surface antigen, and/or positive antibody at the screening visit;
  2. Treatment with an drug within 8 weeks or within 5 half-lives, if known, whichever is longer, before the baseline visit;
  3. Treatment with leukotriene inhibitors within 4 weeks before the baseline visit;
  4. Treatment with systemic within 4 weeks before the baseline visit;
  5. Treatment with topical corticosteroids, tacrolimus, and/or pimecrolimus within 1 week before the baseline visit;
  6. Systemic treatment for AD with an /immunomodulating substance within 4 weeks before the baseline visit;
  7. Chronic or acute infection requiring treatment with oral or IV antibiotics, antivirals, or antifungals within 4 weeks before the screening visit or superficial skin infections within 1 week before the screening visit;
  8. Known history of (HIV) infection;
  9. History of clinical parasite infection, other than treated trichomoniasis;
  10. History of within 5 years before the baseline visit, with the following exceptions: participants with a history of completely treated carcinoma in-situ of cervix, and non- squamous or basal cell carcinoma of the skin were allowed;
  11. Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the participant at risk, interfere with participation in the study, or interfere with the interpretation of study results;
  12. Pregnant or breast-feeding women;
  13. Unwilling to use adequate , if of and sexually active.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Placebo

    Placebo (for Dupilumab) as a single subcutaneous (SC) injection on Day 1, 8, 15, and 22

    Drug: Placebo · Other: Background treatment

  • Experimental
    Dupilumab 150 mg

    Dupilumab 150 mg as a single SC injection on Day 1, 8, 15, and 22

    Drug: Dupilumab · Other: Background treatment

  • Experimental
    Dupilumab 300 mg

    Dupilumab 300 mg as a single SC injection on Day 1, 8, 15, and 22

    Drug: Dupilumab · Other: Background treatment

Interventions

  • DrugPlacebo

    A total of 4 doses were administered.

  • A total of 4 doses were administered.

    Also known as: REGN668, SAR231893, Dupixent

  • OtherBackground treatment

    Participants were required to apply stable doses of an additive-free, basic bland emollient on the affected areas of the skin twice daily throughout the study.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to the end of study visit \[Day 85\]). Any TEAE included participants with both serious and non-serious AEs.

    Time frame: Baseline up to end of study (up to Day 85)

Secondary outcomes

  1. Pharmacokinetics of Dupilumab: Peak Plasma Concentration (Cmax)

    Maximum Plasma Concentration of functional Dupilumab observed following the fourth (last) dose.

    Time frame: Day 22 (pre-dose), 25, 29, 36, 43, 50, 57, 64, 71 and Day 85

  2. Pharmacokinetics of Dupilumab: Last Positive (Quantifiable) Concentration (Clast)

    Last Positive (Quantifiable) Concentration of Dupilumab.

    Time frame: Day 22 (pre-dose), 25, 29, 36, 43, 50, 57, 64, 71 and Day 85

  3. Pharmacokinetics of Dupilumab: Time of the Last Positive (Quantifiable) Concentration (Tlast)

    Mean time of last measurable concentration of Dupilumab in actual days.

    Time frame: Day 22 (pre-dose), 25, 29, 36, 43, 50, 57, 64, 71 and Day 85

Other outcomes

  1. Percentage of Participants with Investigator's Global Assessment (IGA) Score of "0" or "1" at Day 29/ Week 4 (End of Treatment Period)

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of "0" or "1" at Week 4 are reported.

    Time frame: At Day 29/ Week 4

  2. Percent Change From Baseline in Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 4

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined.

    Time frame: Baseline to Day 29/ Week 4

  3. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 4

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Baseline to Day 29/ Week 4

  4. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 4

    SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Day 29/ Week 4

  5. Percent Change From Baseline in 5-D Pruritus Scale to Week 4

    The 5-D Pruritus was a 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponded to 1 of the 5 dimensions of itch. Participants rated their symptoms over the preceding 2-week period on a scale of 1 (least affected) to 5 (most affected). Total score ranges from 1 (least affected) to 25 (most affected).

    Time frame: Baseline to Day 29/ Week 4

  6. Change From Baseline in Average Weekly Pruritus Numerical Rating Scale (NRS) Score to Week 4

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

    Time frame: Baseline to Day 29/ Week 4

07

Study locations

13 sites
  • Kogarah, New South Wales, Australia
  • Woolloongabba, Queensland, Australia
  • Carlton, Victoria, Australia
  • Nedlands, Western Australia, Australia
  • Hannover, Niedersachsen, Germany
  • Bonn, Nordrhein-Westfalen, Germany
  • Berlin, 10117, Germany
  • Berlin, 10827, Germany
  • Gera, Germany
  • Munster, Germany
  • Sydenham, Christchurch, New Zealand
  • Caversham, Dunedin, New Zealand
  • Auckland, New Zealand
08

References and documents

Publications

  • Hamilton JD, Suarez-Farinas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham N, Yancopoulos GD, Pirozzi G, Guttman-Yassky E. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. doi: 10.1016/j.jaci.2014.10.013. PubMed 25482871 ↗
  • Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suarez-Farinas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768. PubMed 25006719 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Mar 2012, 8 months.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 8 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Jun 30, 2011
StartActual
Jul 31, 2011
Primary completionActual
Mar 31, 2012
CompletionActual
Mar 31, 2012
Last update
Feb 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01385657
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jun 30, 2011
Start date
Jul 31, 2011
Primary completion
Mar 31, 2012
Completion
Mar 31, 2012
Last update
Feb 26, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion